Disease · MONDO_0004669
Trials34
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 34
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02564900 | Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | Phase 1 | 292 | 2021-06-23 | Advanced Solid Tumors | TRASTUZUMAB DERUXTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT03172624 | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | Phase 2 | 64 | 2025-12-18 | Salivary Gland Cancer | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00859937 | Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors | Phase 2 | 55 | 2015-04-03 | Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7 | DASATINIB ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | Phase 1/2 | 50 | 2020-10-22 | Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage III Major Salivary Gland Carcinoma, Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | PEMBROLIZUMAB, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02749903 | Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers | Phase 2 | 46 | 2020-01-13 | Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma, Salivary Gland Adenocarcinoma, NOS, Salivary Gland Basal Cell Adenocarcinoma, Stage III Major Salivary Gland Cancer AJCC v7 | ENZALUTAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00095563 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | Phase 2 | 40 | 2017-04-18 | High-grade Salivary Gland Carcinoma, High-grade Salivary Gland Mucoepidermoid Carcinoma, Low-grade Salivary Gland Carcinoma, Low-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Acinic Cell Tumor, Salivary Gland Adenocarcinoma, Salivary Gland Adenoid Cystic Carcinoma, Salivary Gland Malignant Mixed Cell Type Tumor | LAPATINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00509002 | Iressa Study in Patients With Salivary Gland Cancer | Phase 2 | 37 | 2017-11-24 | Salivary Gland Cancer | GEFITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01613768 | Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer | Phase 2 | 29 | 2018-08-10 | Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer | ERIBULIN | Its record names the disease | ClinicalTrials.gov |
| NCT03749460 | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | Phase 1/2 | 20 | 2023-12-29 | Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung, Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IVA Major Salivary Gland Cancer AJCC v8, Stage IVB Major Salivary Gland Cancer AJCC v8, Stage IVC Major Salivary Gland Cancer AJCC v8 | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06581432 | Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Phase 2 | 588 | Solid Tumours | ZONGERTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT01220583 | Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery | Phase 2 | 252 | Head and Neck Cancer | CISPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05087706 | Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS） | 182 | Salivary Gland Neoplasms | BICALUTAMIDE, LEUPROLIDE, PYROTINIB | Its record names the disease | ClinicalTrials.gov | ||
| NCT01969578 | Androgen Deprivation Therapy in Advanced Salivary Gland Cancer | Phase 2 | 149 | Salivary Gland Cancer | BICALUTAMIDE, CARBOPLATIN, CISPLATIN, DOXORUBICIN, PACLITAXEL, TRIPTORELIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05408845 | Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | 146 | Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma | DOCETAXEL, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, TRASTUZUMAB EMTANSINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07464366 | The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study | Phase 2 | 90 | Salivary Gland Carcinomas | BECOTATUG VEDOTIN, PERTUZUMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04209660 | Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers | Phase 2 | 64 | Adenoid Cystic Carcinoma, Salivary Gland Cancer | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04895735 | MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | Phase 2 | 45 | Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma | PEMBROLIZUMAB, PEMETREXED DISODIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT05008237 | Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study | Phase 2 | 42 | Salivary Gland Cancer | CISPLATIN, DOCETAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT03781986 | APG-115 in Salivary Gland Cancer Trial | Phase 1/2 | 41 | Malignant Salivary Gland Cancer, Salivary Gland Cancer | CARBOPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00126607 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | Phase 2 | 35 | High-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Salivary Gland Cancer, Salivary Gland Acinic Cell Tumor, Salivary Gland Adenocarcinoma, Salivary Gland Poorly Differentiated Carcinoma, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer | TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004669/trials